We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+46.69%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$2.05B
AUM Growth
+$352M
Cap. Flow
-$16.5M
Cap. Flow %
-0.81%
Top 10 Hldgs %
43.96%
Holding
116
New
16
Increased
40
Reduced
31
Closed
12

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$31.1M
2
AVLN
Avalyn Pharma
AVLN
+$19.1M
3
PBLS
Parabilis Medicines Inc
PBLS
+$16M
4
COAG
Hemab Therapeutics
COAG
+$15.9M
5
CYTK icon
Cytokinetics
CYTK
+$10.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$37.7M
2
ACLX
Arcellx
ACLX
+$19.5M
3
ELVN icon
Enliven Therapeutics
ELVN
+$15.4M
4
RVMD icon
Revolution Medicines
RVMD
+$15.2M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$44.6B
$207M 10.1%
1,105,210
-104,255
-9% -$15.2M
TVTX icon
2
Travere Therapeutics
TVTX
$6.19B
$124M 6.04%
2,179,069
+701,115
+47% +$31.1M
LLY icon
3
Eli Lilly
LLY
$1.05T
$118M 5.78%
98,700
– –
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$12.3B
$94M 4.59%
174,999
+4,000
+2% +$2.05M
MIRM icon
5
Mirum Pharmaceuticals
MIRM
$5.94B
$93.4M 4.56%
798,145
-13,149
-2% -$1.32M
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$7.38B
$76.9M 3.75%
692,598
+2,850
+0.4% +$258K
KYMR icon
7
Kymera Therapeutics
KYMR
$9.82B
$52M 2.54%
453,156
-43,715
-9% -$3.76M
ARGX icon
8
argenx
ARGX
$64B
$48.9M 2.39%
52,750
-45,750
-46% -$37.7M
ASND icon
9
Ascendis Pharma A/S
ASND
$16.3B
$45M 2.2%
168,750
-25,250
-13% -$5.9M
XENE icon
10
Xenon Pharmaceuticals
XENE
$5.81B
$41.3M 2.01%
683,907
-79,113
-10% -$4.39M
SRRK icon
11
Scholar Rock
SRRK
$7.04B
$39.3M 1.92%
715,452
-24,364
-3% -$1.18M
INSM icon
12
Insmed
INSM
$25.9B
$38.6M 1.88%
362,150
+47,850
+15% +$5.79M
PEN icon
13
Penumbra
PEN
$12.7B
$36.5M 1.78%
115,750
-4,750
-4% -$1.54M
GPCR icon
14
Structure Therapeutics
GPCR
$3.38B
$34.4M 1.68%
640,317
+100
+0% +$4.42K
RARE icon
15
Ultragenyx Pharmaceutical
RARE
$2.52B
$32.3M 1.58%
967,855
-250,918
-21% -$6.23M
IRTC icon
16
iRhythm Holdings
IRTC
$3.96B
$32.1M 1.57%
269,650
+7,900
+3% +$918K
ISRG icon
17
Intuitive Surgical
ISRG
$132B
$30.4M 1.48%
76,460
-5,540
-7% -$2.42M
AGL icon
18
Agilon Health
AGL
$1.55B
$28.1M 1.37%
262,600
+2,600
+1% +$170K
UNH icon
19
UnitedHealth
UNH
$353B
$26.5M 1.29%
63,750
+10,750
+20% +$3.98M
CLDX icon
20
Celldex Therapeutics
CLDX
$3.07B
$26M 1.27%
699,146
+48,876
+8% +$1.58M
ERAS icon
21
Erasca
ERAS
$6.31B
$25.7M 1.25%
1,402,150
+298,681
+27% +$4.27M
NBIX icon
22
Neurocrine Biosciences
NBIX
$15.7B
$24.4M 1.19%
144,750
-5,700
-4% -$846K
ELVN icon
23
Enliven Therapeutics
ELVN
$4.24B
$23.6M 1.15%
464,625
-361,875
-44% -$15.4M
THC icon
24
Tenet Healthcare
THC
$21.5B
$23.4M 1.14%
125,000
– –
DXCM icon
25
DexCom
DXCM
$34.3B
$23.1M 1.13%
343,000
-12,600
-4% -$839K
1
2 3 4 5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Rock Springs Capital Management held 116 positions worth $2.05B, up 21% from $1.7B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Rock Springs Capital Management's Q2 2026 filing shows 16 new, 40 increased, 31 reduced and 12 closed positions. Its largest new stake was Avalyn Pharma: 662,918 shares worth $21.8M. The largest sale was argenx, an estimated $37.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Rock Springs Capital Management's largest Q2 2026 buy was Avalyn Pharma: 662,918 shares worth $21.8M.
  • Rock Springs Capital Management added most to Travere Therapeutics in Q2 2026, an estimated $31.1M increase.
  • Rock Springs Capital Management's biggest Q2 2026 reduction was argenx, cutting an estimated $37.7M.
  • Rock Springs Capital Management fully exited Arcellx in Q2 2026, selling an estimated $19.5M.
  • Rock Springs Capital Management's ten largest holdings make up 44% of its $2.05B portfolio in Q2 2026.
  • Rock Springs Capital Management opened 16 new positions and closed 12 in Q2 2026.
  • Rock Springs Capital Management's portfolio value rose 21% quarter-over-quarter to $2.05B.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.